[EN] CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS<br/>[FR] DÉRIVÉS D'ISOTHIO-URÉE CYCLIQUES UTILISÉS COMME MODULATEURS DU CXCR4
申请人:ERMIUM THERAPEUTICS
公开号:WO2022064075A1
公开(公告)日:2022-03-31
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., systemic lupus erythematosus, dermatomyositis or rheumatoid arthritis.
本发明提供了式(I)的新化合物和含有这些化合物的药物组合物。式(I)的化合物可以作为CXCR4调节剂,特异性靶向CXCR4小口袋,并且已经发现它们抑制免疫细胞中炎性细胞因子的产生,这使得这些化合物在治疗中具有极大的优势,特别是在治疗或预防炎症性疾病、自身免疫性疾病、自身炎症性疾病或干扰素病中,例如系统性红斑狼疮、皮肌炎或类风湿性关节炎。